Cboe UK CHF

Kuros Biosciences AG (KURNZ.XC)

23.00

+3.44

(+17.59%)

As of 3:39 PM GMT. Market Open.

Kuros Biosciences Expands into Extremities Markets

Commercial Highlights Appointment of Jantzen Cole as Vice President of Market Development, Extremities, to drive the Company's acceleration beyond the spine market Strategic expansion opens new addressable market opportunity estimated at $1 billion ...

ACCESSWIRE 9 hours ago

CSBTF
Kuros Reports 149% Increase in Direct MagnetOs Sales and Exceeds Cash Flow Breakeven in the First Nine Months of 2024

Financial Highlights Direct MagnetOsTM sales rose by 149% to CHF 50.6 million in the first nine months of 2024, from CHF 20.4 million in the same period in 2023 Total Kuros Medical Devices segment sales accelerated to CHF 51.1 million in Q3 2024 from ...

ACCESSWIRE last month

CSBTF
Kuros Biosciences Reports First Half of 2024 Results

Financial Highlights Direct MagnetOs™ sales increased by 159% to CHF 31.6 million from CHF 12.2 million in H1 2023; this corresponds to a sequential increase of 62% or CHF 12.1 million over H2 2023 Total Kuros Medical Devices segment sales increased ...

ACCESSWIRE 3 months ago

CSBTF
Kuros Biosciences Announces Peer-Reviewed Publication of MagnetOs MAXA Level 1 Study Outcomes in Spine, Indicating Superiority Over Autograft

ZURICH, SWITZERLAND / ACCESSWIRE / June 25, 2024 / Kuros Biosciences, a leader in next generation bone healing technologies, today announced the publication of a peer-reviewed manuscript that details the clinical data of its MAXA Level 1 prospective, ...

ACCESSWIRE 4 months ago

CSBTF
Kuros Reports Corporate Highlights as of Q1 2024 Including Increase in Direct MagnetOsTM Sales

Financial Highlights Direct MagnetOs sales rose by 155% to CHF 13.9 million in Q1 2024 from CHF 5.4 million in Q1 2023; this corresponds to a sequential increase of 21.9% or CHF 2.5 million over Q4 2023 Total Kuros Medical Devices segment sales accelerated ...

ACCESSWIRE 6 months ago

CSBTF
Annual General Meeting of Kuros Biosciences Approves All Resolutions

ZURICH, SWITZERLAND / ACCESSWIRE / April 17, 2024 / Kuros Biosciences (SIX:KURN), a leader in next generation bone graft technologies, held its Annual General Meeting today. The Annual General Meeting approved the Annual Report, the Annual Financial ...

ACCESSWIRE 6 months ago

CSBTF
Kuros Reports 163% Growth in Direct MagnetOs Sales and 153% Increase in Total Medical Device Sales for the Full Year 2023

Financial highlights Direct MagnetOs sales grew by 163% to CHF 31.7 million in 2023, climbing from CHF 12.1 million in 2022. Total medical device sales accelerated by 153% from CHF 13.3 million in 2022 to CHF 33.6 million in 2023 The Medical Devices ...

ACCESSWIRE 8 months ago

CSBTF
Kuros Biosciences to Report Full Year Financial Results for 2023 and Provide Corporate Update

- Company to host conference call and webcast on March 13, 2024, at 3pm CET/10am US EST SCHLIEREN (ZURICH), SWITZERLAND / ACCESSWIRE / March 8, 2024 / Kuros Biosciences ("Kuros" or "the Company"), a leader in next-generation bone graft technologies, ...

ACCESSWIRE 8 months ago

CSBTF
Kuros Biosciences to Present at the CG 2024 Musculoskeletal Conference

ZURICH, SWITZERLAND / ACCESSWIRE / February 1, 2024 / Kuros Biosciences ("Kuros" or "the Company"), a leader in next generation bone graft technologies, today announced it will present at the CG 2024 Musculoskeletal Conference, to be held in San Francisco ...

ACCESSWIRE 9 months ago

CSBTF
Kuros Biosciences Receives US FDA 510K Clearance for MagnetOs Granules for Interbody Use and Regulatory Clearance of MagnetOs Granules and MagnetOs Putty in New Zealand

MagnetOs ™ Granules becomes the third product in the MagnetOs portfolio to receive FDA clearance to market for interbody use Kuros continues expansion of the MagnetOs franchise with launch of MagnetOs Granules and MagnetOs Putty in New Zealand via ...

ACCESSWIRE 9 months ago

CSBTF
Kuros Biosciences Announces Three Advancements Related to its MagnetOsTM Portfolio Including Impressive Fusion Data from MAXA Prospective Randomized Clinical Trial and Two 510(k) Clearances from FDA

New level 1 data from the MAXA Clinical Trial comparing standalone MagnetOs to the gold standard autograft in the challenging posterior spinal fusion approach, demonstrates a fusion rate of 78% versus 45% after one year In the difficult-to-treat patient ...

ACCESSWIRE 10 months ago

CSBTF
Kuros Biosciences Announces Results from Two Prospective Randomized Clinical Trials: STRUCTURE and MAXA

In the MAXA trial, standalone MagnetOs outperformed the gold standard autograft by 73% in posterior spinal fusion in a difficult-to-treat real life patient population (20% smokers). In the STRUCTURE trial, MagnetOs mixed with autograft showed posterolateral ...

ACCESSWIRE 10 months ago

CSBTF
Kuros Biosciences Receives FDA Clearance for Use of MagnetOs in Interbody Spinal Cages

MagnetOs is the first open fibrillar collagen matrix bone graft substitute to receive clearance to market for interbody useMagnetOs can now be used on-label in any interbody cage cleared for use with a bone void fillerThe exceptional handling properties ...

ACCESSWIRE 11 months ago

CSBTF

Performance Overview

Return	KURNZ.XC	MSCI WORLD
YTD	+574.49%	+17.40%
1-Year	+476.44%	+24.63%
3-Year	+210.81%	+15.31%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Kuros Biosciences AG (KURNZ.XC)

Kuros Biosciences Expands into Extremities Markets

Kuros Reports 149% Increase in Direct MagnetOs Sales and Exceeds Cash Flow Breakeven in the First Nine Months of 2024

Kuros Biosciences Reports First Half of 2024 Results

Kuros Biosciences Announces Peer-Reviewed Publication of MagnetOs MAXA Level 1 Study Outcomes in Spine, Indicating Superiority Over Autograft

Kuros Reports Corporate Highlights as of Q1 2024 Including Increase in Direct MagnetOsTM Sales

Annual General Meeting of Kuros Biosciences Approves All Resolutions

Kuros Reports 163% Growth in Direct MagnetOs Sales and 153% Increase in Total Medical Device Sales for the Full Year 2023

Kuros Biosciences to Report Full Year Financial Results for 2023 and Provide Corporate Update

Kuros Biosciences to Present at the CG 2024 Musculoskeletal Conference

Kuros Biosciences Receives US FDA 510K Clearance for MagnetOs Granules for Interbody Use and Regulatory Clearance of MagnetOs Granules and MagnetOs Putty in New Zealand

Kuros Biosciences Announces Three Advancements Related to its MagnetOsTM Portfolio Including Impressive Fusion Data from MAXA Prospective Randomized Clinical Trial and Two 510(k) Clearances from FDA

Kuros Biosciences Announces Results from Two Prospective Randomized Clinical Trials: STRUCTURE and MAXA

Kuros Biosciences Receives FDA Clearance for Use of MagnetOs in Interbody Spinal Cages

Performance Overview